NCT01604681

Brief Summary

The purpose of this study is to evaluate the effect of supplementation with flaxseed oil combined with a nutritional counseling in reducing cardiovascular risk factors in homocysteine , biomarkers of inflammation, oxidative stress, improving quality of life and cognitive decline in hypertensive and dyslipidemic genotyped for the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P50-P75 for not_applicable hypertension

Timeline
Completed

Started Jan 2011

Typical duration for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

May 18, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 24, 2012

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

May 24, 2012

Status Verified

December 1, 2010

Enrollment Period

1.9 years

First QC Date

May 18, 2012

Last Update Submit

May 23, 2012

Conditions

Keywords

Linseed OilOxidative StressPolymorphism, GeneticCardiovascular Diseases

Outcome Measures

Primary Outcomes (1)

  • Polymorphisms

    To evaluate the effect of nutritional counseling associated with linseed oil supplementation on biomarkers estutados according to the C677T and A1298C polymorphisms of the MTHFR gene.

    Up to 3 months

Secondary Outcomes (4)

  • Cognitive decline

    Up to 3 months

  • Quality of life

    Up to 3 months

  • Oxidative stress

    Up to 3 months

  • Lipid profile

    Up to 3 months

Study Arms (2)

placebo group

PLACEBO COMPARATOR

3 g of powdered gelatin encapsulated in opaque capsules.

Dietary Supplement: Placebo

Flaxseed oil group

EXPERIMENTAL

Oil extracted from linseed by pressing the cold and encapsulated, providing 3g per day containing 1.75 g of alpha linolenic acid.

Dietary Supplement: Flaxseed Oil

Interventions

PlaceboDIETARY_SUPPLEMENT

6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.

Also known as: Control group
placebo group
Flaxseed OilDIETARY_SUPPLEMENT

6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.

Also known as: Linseed Oil
Flaxseed oil group

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of hypertension and/or dyslipidemia,
  • Have over 20 years,
  • Both sexes,
  • Any skin color and
  • Take part in the study by signing the consent form.

You may not qualify if:

  • Make use of some food or vitamin supplement,
  • HIV positive and cancer.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clementino Fraga Filho University Hospital Rio de Janeiro

Rio de Janeiro, Rio de Janeiro, Brazil

RECRUITING

MeSH Terms

Conditions

HypertensionDyslipidemiasCardiovascular Diseases

Interventions

Control GroupsLinseed Oil

Condition Hierarchy (Ancestors)

Vascular DiseasesLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethodsFats, UnsaturatedFatsLipidsPlant OilsOilsPlant PreparationsBiological ProductsComplex Mixtures

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 18, 2012

First Posted

May 24, 2012

Study Start

January 1, 2011

Primary Completion

December 1, 2012

Study Completion

December 1, 2013

Last Updated

May 24, 2012

Record last verified: 2010-12

Locations